Tarsus Pharmaceuticals (TARS) Amortization of Deferred Charges (2022 - 2026)

Tarsus Pharmaceuticals' Amortization of Deferred Charges history runs 5 years deep, the most recent figure standing at $159000.0 for Q1 2026.

• In Q1 2026, Amortization of Deferred Charges rose 14.39% year-over-year to $159000.0; the TTM figure through Mar 2026 stood at $613000.0 (up 4.43% YoY), while the FY2025 annual figure was $593000.0, up 23.03% from the prior year.
• Amortization of Deferred Charges was $159000.0 for Q1 2026 at Tarsus Pharmaceuticals, up from $156000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $295000.0 in Q4 2023 to a low of $28000.0 in Q2 2023.
• Historically, Amortization of Deferred Charges has averaged $112529.4 across 5 years, with a median of $114000.0 in 2024.
• The sharpest annual moves came in 2023 and 2024: Amortization of Deferred Charges plunged 47.27% in 2023, then soared 293.1% in 2024.
• A 5-year view of Amortization of Deferred Charges shows it stood at $78000.0 in 2022, then soared by 278.21% to $295000.0 in 2023, then dropped by 26.1% to $218000.0 in 2024, then declined by 28.44% to $156000.0 in 2025, then climbed by 1.92% to $159000.0 in 2026.
• The last three Amortization of Deferred Charges figures came in at $159000.0 (Q1 2026), $156000.0 (Q4 2025), and $152000.0 (Q3 2025), per Business Quant data.